Venetoclax in Acute Myeloid Leukemia: Evolving Landscape, Resistance Mechanisms, and Future Directions
Abstract Venetoclax, a potent and selective BCL-2 inhibitor, has revolutionized the treatment paradigm for acute myeloid leukemia (AML), particularly in older or unfit patients ineligible for intensive chemotherapy. Its combination with hypomethylating agents (HMAs) such […]
